Division of Hematology and Oncology

Jordan Berlin, MD, was recognized for his leadership serving on an NCI team that researched and recommended changes to clinical trial protocols that expanded the role of advanced practice providers.

National Cancer Institute honors Berlin’s contributions, leadership

Vanderbilt’s Jordan Berlin, MD, is a 2022 recipient of the National Cancer Institute Director’s Award.

New treatment helps mitigate hair loss for chemotherapy patients

Vanderbilt-Ingram Cancer Center has started offering scalp cooling, which mitigates hair loss for patients receiving certain chemotherapy regimens.

VUMC researcher selected for Global Scholars Program

Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.

Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

Eng stresses need for clinical trial support at cancer forum

Vanderbilt’s Cathy Eng, MD, stressed the need for more patient participation and better funding for clinical trials to improve colorectal cancer treatment and outcomes during the White House Cancer Moonshot Colorectal Cancer Forum.

Eng invited to White House Cancer Moonshot forum

Vanderbilt’s Cathy Eng, MD, has been invited to participate in the White House Cancer Moonshot Colorectal Cancer Forum.

1 2 3 4 5 6 16